[go: up one dir, main page]

MA41937B1 - Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 - Google Patents

Conjugués de médicaments comprenant des anticorps contre la claudine 18.2

Info

Publication number
MA41937B1
MA41937B1 MA41937A MA41937A MA41937B1 MA 41937 B1 MA41937 B1 MA 41937B1 MA 41937 A MA41937 A MA 41937A MA 41937 A MA41937 A MA 41937A MA 41937 B1 MA41937 B1 MA 41937B1
Authority
MA
Morocco
Prior art keywords
cancer
claudine
antibodies
drug conjugates
conjugates including
Prior art date
Application number
MA41937A
Other languages
English (en)
Other versions
MA41937A (fr
Inventor
Ugur Sahin
Özlem Türeci
Korden Walter
Maria Kreuzberg
Rita Mitnacht-Kraus
Gall Fabrice Le
Stefan Jacobs
Original Assignee
Astellas Pharma Inc
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Astellas Pharma Inc
Publication of MA41937A publication Critical patent/MA41937A/fr
Publication of MA41937B1 publication Critical patent/MA41937B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des conjugués médicament-anticorps anti-cldn18.2 qui sont efficaces pour traiter et/ou prévenir des cancers associés à des cellules exprimant cldn18.2, dont le cancer de l'estomac, le cancer de l'œsophage, le cancer du pancréas, le cancer du poumon, le cancer de l'ovaire, le cancer du côlon, le cancer du foie, le cancer de la tête et du cou et le cancer de la vésicule biliaire et leurs métastases.
MA41937A 2015-04-15 2016-04-13 Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 MA41937B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/058206 WO2016165762A1 (fr) 2015-04-15 2015-04-15 Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
PCT/EP2016/058056 WO2016166122A1 (fr) 2015-04-15 2016-04-13 Conjugués de médicaments comprenant des anticorps contre la claudine 18.2

Publications (2)

Publication Number Publication Date
MA41937A MA41937A (fr) 2018-02-28
MA41937B1 true MA41937B1 (fr) 2023-12-29

Family

ID=52875694

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41937A MA41937B1 (fr) 2015-04-15 2016-04-13 Conjugués de médicaments comprenant des anticorps contre la claudine 18.2

Country Status (29)

Country Link
US (2) US11541127B2 (fr)
EP (2) EP3283521B1 (fr)
JP (4) JP6800883B2 (fr)
KR (4) KR102336566B1 (fr)
CN (1) CN107667118A (fr)
AU (1) AU2016249782B2 (fr)
BR (1) BR112017018521A2 (fr)
CA (1) CA2982401C (fr)
DK (1) DK3283521T5 (fr)
ES (1) ES2964813T3 (fr)
FI (1) FI3283521T3 (fr)
HK (1) HK1247210A1 (fr)
HR (1) HRP20231609T1 (fr)
HU (1) HUE064753T2 (fr)
IL (2) IL254085B2 (fr)
LT (1) LT3283521T (fr)
MA (1) MA41937B1 (fr)
MD (1) MD3283521T2 (fr)
MX (2) MX2023013476A (fr)
PL (1) PL3283521T3 (fr)
PT (1) PT3283521T (fr)
RS (1) RS64951B1 (fr)
RU (2) RU2017139490A (fr)
SG (2) SG11201708271TA (fr)
SI (1) SI3283521T1 (fr)
SM (1) SMT202300455T1 (fr)
UA (1) UA127469C2 (fr)
WO (2) WO2016165762A1 (fr)
ZA (1) ZA201705923B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678127C2 (ru) 2012-11-13 2019-01-23 Бионтех Аг Агенты для лечения экспрессирующих клаудин раковых заболеваний
WO2016165762A1 (fr) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
TW201920192A (zh) 2017-09-20 2019-06-01 韓商Ｐｈ製藥公司 泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物
US11555070B2 (en) 2018-03-08 2023-01-17 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
MX2020009514A (es) * 2018-03-14 2020-12-07 Beijing Xuanyi Pharmasciences Co Ltd Anticuerpos anti-claudina 18.2 (cldn18.2).
JP7117795B2 (ja) * 2018-05-18 2022-08-15 ラノバ メディシンズ リミテッド 抗クローディン１８．２抗体およびその使用
CN110606891B (zh) * 2018-06-17 2022-12-06 上海健信生物医药科技有限公司 一种针对人cldn18.2的抗体分子，抗原结合片段及其医药用途
US11912763B2 (en) 2018-06-17 2024-02-27 L & L Biopharma Co., Ltd. Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof
WO2020009165A1 (fr) * 2018-07-03 2020-01-09 味の素株式会社 Anticorps modifié et procédé pour sa production
US11505618B2 (en) * 2018-07-18 2022-11-22 Askgene Pharma Inc. Antibodies and methods for making and using the same
CN110857322A (zh) 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
WO2020038404A1 (fr) * 2018-08-22 2020-02-27 瑞阳(苏州)生物科技有限公司 Anticorps monoclonal anti-claudine 18,2 humaine et son utilisation
CA3110593A1 (fr) * 2018-08-27 2020-03-05 Nanjing Sanhome Pharmaceutical Co., Ltd. Anticorps anti-claudin18.2 et son utilisation
KR20210093879A (ko) * 2018-10-22 2021-07-28 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. 항-cldn18.2 항체 및 이의 용도
US20210380680A1 (en) * 2018-12-07 2021-12-09 ZLlP HOLDING LIMITED Anti-claudin antibodies and uses thereof
BR112021012608A2 (pt) * 2018-12-28 2021-09-08 Nanjing GenScript Biotech Co., Ltd. Porção de ligação que se liga especificamente à claudina18.2, receptor de antígeno quimérico, ácido nucleico, célula imune manipulada, composição farmacêutica, e, método de tratamento de um tumor ou câncer que expressa claudina18.2
CN113166246B (zh) * 2018-12-28 2024-10-18 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
CN111434692B (zh) * 2019-01-15 2021-12-31 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
EP3917564A4 (fr) * 2019-02-01 2022-12-21 NovaRock Biotherapeutics, Ltd. Anticorps anti-claudine 18 et leurs méthodes d'utilisation
AU2020253792A1 (en) * 2019-03-29 2021-09-09 Phanes Therapeutics, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
CN116063516A (zh) 2019-04-01 2023-05-05 江苏恒瑞医药股份有限公司 抗Claudin18.2抗体及其应用
CN117659190A (zh) * 2019-05-16 2024-03-08 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
WO2020228806A1 (fr) * 2019-05-16 2020-11-19 齐鲁制药有限公司 Anticorps dirigé contre la claudine 18a2 et son utilisation
CN113891731A (zh) * 2019-05-22 2022-01-04 小利兰·斯坦福大学理事会 药物缀合物及其使用方法
US20220204609A1 (en) * 2019-05-30 2022-06-30 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2
WO2021011885A1 (fr) * 2019-07-17 2021-01-21 The Regents Of The University Of California Anticorps dirigés contre la claudine 18 et méthodes de traitement du cancer
JP2022545660A (ja) * 2019-08-20 2022-10-28 スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド 新規抗ｃｌｄｎ１８．２抗体
TW202124442A (zh) * 2019-09-13 2021-07-01 大陸商北京軒義醫藥科技有限公司 人源化抗ｃｌｄｎ１８．２抗體、編碼其的核酸分子、其產生方法、包含其的組合物、試劑盒及其用途
CN112707965A (zh) * 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
CN114269389B (zh) * 2019-11-05 2022-12-27 礼新医药科技(上海)有限公司 靶向紧密连接蛋白18.2的抗体药物偶联物
EP4069738A1 (fr) 2019-12-06 2022-10-12 SOTIO Biotech a.s. Anticorps humanisés anti-cldn18.2
BR112022011032A2 (pt) * 2019-12-12 2022-08-16 Jiangsu Hengrui Medicine Co Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
MX2022007849A (es) 2019-12-23 2022-07-19 Sotio Biotech A S Anticuerpos especificos contra la claudina 18.2 tumoral.
BR112022012524A2 (pt) * 2019-12-27 2022-12-20 Nanjing Legend Biotech Co Ltd Porção química de ligação que se liga especificamente a claudin18.2, polinucleotídeo, vetor, célula hospedeira, receptor de antígeno quimérico (car ), célula imune geneticamente modificada, composição farmacêutica, método de tratamento de um tumor ou câncer que expressa claudin18.2
US20230331836A1 (en) * 2020-05-25 2023-10-19 Suzhou Transcenta Therapeutics Co., Ltd. Anti-cldn18.2 antibodies and diagnostic uses thereof
CN115943162A (zh) * 2020-06-19 2023-04-07 信达生物制药(苏州)有限公司 抗Claudin18.2抗体以及其用途
TW202216770A (zh) * 2020-06-23 2022-05-01 香港商德琪生物有限公司 用於治療密連蛋白相關疾病之抗體及方法
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
US20230312725A1 (en) 2020-08-28 2023-10-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Signal peptide for reducing end heterogeneity of heterologous polypeptide
IL301658A (en) * 2020-09-30 2023-05-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
CR20230207A (es) * 2020-10-15 2023-10-26 Keymed Biosciences Co Ltd Conjugado anticuerpo-fármaco y aplicación del mismo
WO2022100590A1 (fr) * 2020-11-10 2022-05-19 齐鲁制药有限公司 Anticorps humanisé enrichi en adcc pour claudin 18a2 et application associée
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
KR20230135045A (ko) 2020-11-30 2023-09-22 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 항-cldn18.2 항체, 약물 결합체 및 이의 제조 방법 및 용도
WO2022122709A1 (fr) 2020-12-07 2022-06-16 Sotio Biotech A.S. Conjugués anticorps-médicament à base d'anticorps cldn18.2 humanisés
CA3199830A1 (fr) 2020-12-23 2022-06-30 Lukas BAMMERT Conjugues anticorps-medicament anti-claudine 18.2 specifiques d'une tumeur
WO2022171134A1 (fr) * 2021-02-09 2022-08-18 江苏迈威康新药研发有限公司 Conjugué anticorps-médicament comprenant un anticorps anti-cldn18.2 ou un fragment de liaison à l'antigène de celui-ci et son utilisation
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
EP4393515A1 (fr) * 2021-08-26 2024-07-03 Shanghai Junshi Biosciences Co., Ltd. Conjugué anticorps-médicament anti-cldn-18.2 et son utilisation
CN115991784A (zh) 2021-10-19 2023-04-21 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体及其用途
AU2023278315A1 (en) 2022-05-31 2024-12-12 CSPC Megalith Biopharmaceutical Co., Ltd. Pharmaceutical composition of recombinant anti-human cldn18.2 monoclonal antibody-mmae conjugate
CN117143237A (zh) * 2022-06-01 2023-12-01 百奥泰生物制药股份有限公司 抗cldn18.2抗体及其抗体药物偶联物和用途
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CN115969997B (zh) * 2022-12-19 2024-02-13 华润生物医药有限公司 一种靶向cldn18.2的抗体药物偶联物及其应用
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires
WO2024255880A1 (fr) * 2023-06-16 2024-12-19 Fortvita Biologics (Singapore) Pte. Ltd. Procédé de traitement de tumeurs solides avec un conjugué anticorps-médicament ciblant la claudine 18,2

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2004035607A2 (fr) 2002-10-17 2004-04-29 Genmab A/S Anticorps monoclonaux humains anti-cd20
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1997832A1 (fr) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
WO2010146059A2 (fr) * 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
KR20140009275A (ko) * 2010-12-09 2014-01-22 제넨테크, 인크. 파클리탁셀 및 트라스투주맙-mcc-dm1에 의한 her2-양성 암의 치료
EP2793585A4 (fr) * 2011-12-05 2015-12-09 Igenica Biotherapeutics Inc Conjugués anticorps-médicament et composés, compositions et méthodes connexes
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
WO2015014376A1 (fr) * 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
WO2016165762A1 (fr) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
WO2016165765A1 (fr) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer

Also Published As

Publication number Publication date
PL3283521T3 (pl) 2024-01-29
KR102626316B1 (ko) 2024-01-18
KR20240011250A (ko) 2024-01-25
DK3283521T3 (da) 2023-12-18
JP2021038255A (ja) 2021-03-11
SMT202300455T1 (it) 2024-01-10
IL314928A (en) 2024-10-01
MX2017013075A (es) 2018-02-19
BR112017018521A2 (pt) 2018-04-17
CA2982401C (fr) 2024-06-11
EP3283521A1 (fr) 2018-02-21
IL254085A0 (en) 2017-10-31
JP2024036444A (ja) 2024-03-15
EP4331578A3 (fr) 2024-06-05
KR102401299B1 (ko) 2022-05-24
US11541127B2 (en) 2023-01-03
KR102336566B1 (ko) 2021-12-23
UA127469C2 (uk) 2023-09-06
WO2016165762A1 (fr) 2016-10-20
CN107667118A (zh) 2018-02-06
HK1247210A1 (zh) 2018-09-21
EP3283521B1 (fr) 2023-11-15
JP2022031979A (ja) 2022-02-22
SG10202105142VA (en) 2021-06-29
IL254085B1 (en) 2024-09-01
LT3283521T (lt) 2023-12-27
JP2018513146A (ja) 2018-05-24
MD3283521T2 (ro) 2024-03-31
RU2021131990A (ru) 2022-02-04
IL254085B2 (en) 2025-01-01
WO2016166122A1 (fr) 2016-10-20
PT3283521T (pt) 2023-12-18
AU2016249782A1 (en) 2017-11-02
AU2016249782B2 (en) 2022-04-28
DK3283521T5 (da) 2024-10-07
MA41937A (fr) 2018-02-28
RU2017139490A (ru) 2019-05-15
CA2982401A1 (fr) 2016-10-20
JP6800883B2 (ja) 2020-12-16
RU2017139490A3 (fr) 2020-01-17
HUE064753T2 (hu) 2024-04-28
SG11201708271TA (en) 2017-11-29
JP7024152B2 (ja) 2022-02-24
EP4331578A2 (fr) 2024-03-06
SI3283521T1 (sl) 2024-04-30
KR20210150612A (ko) 2021-12-10
ZA201705923B (en) 2019-06-26
RS64951B1 (sr) 2024-01-31
ES2964813T3 (es) 2024-04-09
US20180117174A1 (en) 2018-05-03
US20230270878A1 (en) 2023-08-31
HRP20231609T1 (hr) 2024-03-15
KR20180082325A (ko) 2018-07-18
FI3283521T3 (fi) 2023-12-12
KR20220072874A (ko) 2022-06-02
MX2023013476A (es) 2023-12-15

Similar Documents

Publication Publication Date Title
MA41937B1 (fr) Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
IL268888A (en) Multispecific binding proteins targeting CAIX, ANOI, mesothelin, TROP2, CEA, or CLAUDIN-18.2
NZ752526A (en) Pyrrolobenzodiazepine conjugates
HK1259487A1 (zh) 特定的共軛連接子，特定的免疫共軛物，製造和使用這些共軛物的方法
IL279133A (en) Binder-drug conjugates activated in the microenvironment and their related uses
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
MX2019009441A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011771A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
PH12018500285A1 (en) Bridge linkers for conjugation of a cell-binding molecule
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
WO2017031458A3 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
SA520412283B1 (ar) Cd22 أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ
EP4364756A3 (fr) Polythérapie impliquant des anticorps contre la claudine 18.2 pour le traitement du cancer
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
SA519401424B1 (ar) Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها
MX2018011219A (es) Trail diseñado por ingenieria para terapia de cancer.
MX2019004410A (es) Particulas citotoxicas.